You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global Diabetic Nephropathy Market Size, Status and Forecast 2020-2026

Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.
Market Analysis and Insights: Global Diabetic Nephropathy Market
The global Diabetic Nephropathy market size is projected to reach US$ 3337.8 million by 2026, from US$ 2522.4 million in 2020, at a CAGR of 4.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Nephropathy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Nephropathy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Nephropathy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Nephropathy market.
Diabetic Nephropathy Breakdown Data by Type
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Diabetic Nephropathy Breakdown Data by Application
Hospitals
Cancer Research Institutes
Diagnostic Labs
Based on regional and country-level analysis, the Diabetic Nephropathy market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Diabetic Nephropathy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The following players are covered in this report:
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
Mitsubishi Tanabe Pharma
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Nephropathy Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 ACE Inhibitors
1.2.3 ARBs
1.2.4 Diuretics
1.2.5 Calcium Channel Blockers(CCBs)
1.2.6 Renin Inhibitors
1.2.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.2.8 Antioxidant Inflammation Modulators(AIMs)
1.2.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.2.10 Endothelin-A Receptor(ETAR)Antagonist
1.2.11 G Protein-Coupled Receptors (GPCRs)
1.3 Market by Application
1.3.1 Global Diabetic Nephropathy Market Share by Application: 2020 VS 2026
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Labs
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Nephropathy Market Perspective (2015-2026)
2.2 Global Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Nephropathy Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Nephropathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Market Size
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2015-2020)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Players (2015-2020)
3.2 Global Diabetic Nephropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
3.4 Global Diabetic Nephropathy Market Concentration Ratio
3.4.1 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2019
3.5 Key Players Diabetic Nephropathy Area Served
3.6 Key Players Diabetic Nephropathy Product Solution and Service
3.7 Date of Enter into Diabetic Nephropathy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Diabetic Nephropathy Breakdown Data by Type (2015-2026)
4.1 Global Diabetic Nephropathy Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Nephropathy Forecasted Market Size by Type (2021-2026)

5 Diabetic Nephropathy Breakdown Data by Application (2015-2026)
5.1 Global Diabetic Nephropathy Historic Market Size by Application (2015-2020)
5.2 Global Diabetic Nephropathy Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Diabetic Nephropathy Market Size (2015-2026)
6.2 North America Diabetic Nephropathy Market Size by Type (2015-2020)
6.3 North America Diabetic Nephropathy Market Size by Application (2015-2020)
6.4 North America Diabetic Nephropathy Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada

7 Europe
7.1 Europe Diabetic Nephropathy Market Size (2015-2026)
7.2 Europe Diabetic Nephropathy Market Size by Type (2015-2020)
7.3 Europe Diabetic Nephropathy Market Size by Application (2015-2020)
7.4 Europe Diabetic Nephropathy Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe

8 China
8.1 China Diabetic Nephropathy Market Size (2015-2026)
8.2 China Diabetic Nephropathy Market Size by Type (2015-2020)
8.3 China Diabetic Nephropathy Market Size by Application (2015-2020)
8.4 China Diabetic Nephropathy Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific

9 Japan
9.1 Japan Diabetic Nephropathy Market Size (2015-2026)
9.2 Japan Diabetic Nephropathy Market Size by Type (2015-2020)
9.3 Japan Diabetic Nephropathy Market Size by Application (2015-2020)
9.4 Japan Diabetic Nephropathy Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil

10 Southeast Asia
10.1 Southeast Asia Diabetic Nephropathy Market Size (2015-2026)
10.2 Southeast Asia Diabetic Nephropathy Market Size by Type (2015-2020)
10.3 Southeast Asia Diabetic Nephropathy Market Size by Application (2015-2020)
10.4 Southeast Asia Diabetic Nephropathy Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Diabetic Nephropathy Introduction
11.1.4 Novartis Revenue in Diabetic Nephropathy Business (2015-2020))
11.1.5 Novartis Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Diabetic Nephropathy Introduction
11.2.4 Merck Revenue in Diabetic Nephropathy Business (2015-2020)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Diabetic Nephropathy Introduction
11.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2015-2020)
11.3.5 Pfizer Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
11.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2015-2020)
11.4.5 Abbott Laboratories Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Diabetic Nephropathy Introduction
11.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2015-2020)
11.5.5 Sanofi Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Diabetic Nephropathy Introduction
11.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2015-2020)
11.6.5 Eli Lilly Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Diabetic Nephropathy Introduction
11.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2015-2020)
11.7.5 AbbVie Recent Development
11.8 Reata Pharmaceuticals
11.8.1 Reata Pharmaceuticals Company Details
11.8.2 Reata Pharmaceuticals Business Overview
11.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
11.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2015-2020)
11.8.5 Reata Pharmaceuticals Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Diabetic Nephropathy Introduction
11.9.4 Bayer Revenue in Diabetic Nephropathy Business (2015-2020)
11.9.5 Bayer Recent Development
11.10 Mitsubishi Tanabe Pharma
11.10.1 Mitsubishi Tanabe Pharma Company Details
11.10.2 Mitsubishi Tanabe Pharma Business Overview
11.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
11.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2015-2020)
11.10.5 Mitsubishi Tanabe Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
  • FORMAT: PDF
  • PUBLISHED DATE: Sep, 2020
  • NO OF PAGES: 134